Figure 1





Figure 2



Figure

, C	351 QGQVHPNYFWMVSGCVEPPPSWKPQQMPPPEEPL	351
350	AAGVMHLFYVRAGVSRAMLLRLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKGMFAVDGELMVSEAV	281
280	AYLPVGRVGSKTPASPVVVQQGPVDAHLVPLEEPVPSHATYVPDEDFVLVLALLHSHLGSEMFAAPMGRC	211
210	llcrri (S) mnilsihtasgirifsvislawgfiadvdi (S)ky rigemrftigtfirlaalrtyrgri	141
140	RWDALVVMSGDGLMHEVVNGLMERPDWETAIQKPLCSLPAGSGNALAASLNHYAGYEQVTNEDLLTNCTL	71
70	MDPAGGPRGVLPRPCRVLVLLNPRGGKGKALQLFKSHVQPLLAEAEISFTLMLTERRNHARELVRSEELG	H

Figure 4




Figure 5

	hSK ^{S225A}		hSKWT		hSK ^{S220A}		hSK ^{T222A}	
PMA	-	+	-	+	_	+	-	. +
				^				
L		 		·				

Figure 6




Figure 7





Figure 8






Figure 10A




Figure 10B




Figure 10C




Figure 11




Figure 12

(eg. Drugs targeting ATP or Sphingosine binding sites) antagonists directly targeting the catalytic activity Protein kinase (Erk2?) antagonists targeting activation

Figure 13




Figure 14




Figure 15




Figure 16






Figure 17









Figure 18 substitute sheet (RULE 26) RO/AU






Figure 18 SUBSTITUTE SHEET (RULE 26) RO/AU